Overview of Race Oncology’s new “5 path” strategy for the development of Bisantrene.
• Introduction & Welcome | Mr Peter Molloy CEO/MD (0.00 – 10.00)
• Race’s 5 Path Strategy | Dr Daniel Tillett CSO (10.00 – 39.00)
• Conclusion | Mr Peter Molloy CEO/MD (39.01 – 45.23)
Videography and editing by Sirius Productions